ClinicalTrials.gg

Program

tremelimumab

Also written as “Tremelimumab”, “CP-675,206” and “MEDI4736 + tremelimumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Melanoma · Small Cell Lung Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Furthest: phase 3, since Nov 18, 200547 company-led studies, 18 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca4618 open or runningphase 3since Nov 18, 2005Jul 1, 2004Nov 30, 2026phase 2 · NCT07081633
Pfizer10 open or runningphase 2since Jun 19, 2007Jun 19, 2007none ahead

Also a collaborator on its studies: pra-health-sciences and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Jul 1, 2004.

  1. Nov 8, 2016Phase 1 study in Advanced MalignancyAstraZeneca · NCT02978482 · 26 enrolled · China
  2. Jan 18, 2017Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT03043872 · 987 enrolled · United States, Argentina, Austria and more
  3. May 22, 2017Phase 3 study in Non Small Cell Lung Cancer NSCLCAstraZeneca · NCT03164616 · 1,186 enrolled · United States, Brazil, Bulgaria and more
  4. Sep 19, 2017Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT03298451 · 1,324 enrolled · United States, Brazil, Canada and more
  5. Mar 12, 2018Phase 1 study in Squamous Cell Carcinoma of Head and NeckAstraZeneca · NCT03509012 · 105 enrolled · United States, Japan, Korea, Republic of and more
  6. Sep 6, 20182 phase 3 studiesAstraZeneca · NCT03682068, NCT03703297
  7. Jan 24, 2019Phase 2 study in NeoplasmsAstraZeneca · NCT03837899 · 50 enrolled · United States, France, Germany and more
  8. Jun 17, 2021Phase 3 study in Urinary Bladder NeoplasmsAstraZeneca · NCT04960709 · 712 enrolled · United States, Argentina, Austria and more
  9. Mar 21, 2022Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT05301842 · 760 enrolled · United States, Belgium, Brazil and more
  10. Sep 14, 2022Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT05557838 · 214 enrolled · China
  11. May 22, 2023Phase 3 study in Liver NeoplasmsAstraZeneca · NCT05883644 · 111 enrolled · United States, France, Germany and more
  12. Aug 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06008093 · 103 enrolled · United States
  13. Mar 26, 2025Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT06921785 · 1,220 planned · United States, Australia, Brazil and more
  14. Jun 23, 2025Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633 · 114 enrolled · China, Hong Kong

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633
  2. Mar 15, 2030Primary completion: phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT06921785

TargetBeta

CTLA4 →read by rule
“A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4)”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

All 47 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07081633Carcinoma, Hepatocellular · China, Hong Kong2Active, not recruitingAstraZenecaNov 30, 2026114
NCT06921785Carcinoma, Hepatocellular · United States, Australia, Brazil and more3RecruitingAstraZenecaMar 15, 20301,220
NCT06008093Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingAstraZenecaOct 27, 2026103
NCT05883644Liver Neoplasms · United States, France, Germany and more3Active, not recruitingAstraZenecaMar 30, 2026111
NCT05557838Carcinoma, Hepatocellular · China3Active, not recruitingAstraZenecaSep 30, 2026214
NCT05301842Carcinoma, Hepatocellular · United States, Belgium, Brazil and more3Active, not recruitingAstraZenecaFeb 23, 2026760
NCT04960709Urinary Bladder Neoplasms · United States, Argentina, Austria and more3Active, not recruitingAstraZenecaMar 2, 2026712
NCT03837899Neoplasms · United States, France, Germany and more2Active, not recruitingAstraZenecaFeb 28, 202350
NCT03703297Small Cell Lung Carcinoma · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaJan 15, 2024730
NCT03682068Urinary Bladder Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaJun 1, 20261,246
NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more1CompletedAstraZenecaDec 31, 2020105
NCT03298451Carcinoma, Hepatocellular · United States, Brazil, Canada and more3Active, not recruitingAstraZenecaAug 27, 20211,324
NCT03164616Non Small Cell Lung Cancer NSCLC · United States, Brazil, Bulgaria and more3Active, not recruitingAstraZenecaMar 12, 20211,186
NCT03043872Small Cell Lung Carcinoma · United States, Argentina, Austria and more3Active, not recruitingAstraZenecaJan 27, 2020987
NCT02978482Advanced Malignancy · China1CompletedAstraZenecaJan 28, 201826
NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more2CompletedAstraZenecaJun 22, 202072
NCT02658214Small Cell Lung Carcinoma · Japan, Korea, Republic of1CompletedAstraZenecaNov 14, 201932
NCT02551159Squamous Cell Carcinoma of Head and Neck · United States, Austria, Belgium and more3CompletedAstraZenecaJul 6, 2020823
NCT02558894Anophthalmia with pulmonary hypoplasia · United States, Canada, Germany and more2CompletedAstraZenecaJun 15, 201765
NCT02549651Lymphoma, Large B-Cell, Diffuse · United States, France, Ireland and more1CompletedAstraZenecaFeb 4, 201932
NCT02542293Non Small Cell Lung Carcinoma NSCLC · United States, Argentina, Brazil and more3Active, not recruitingAstraZenecaSep 21, 2020953
NCT02527434Triple Negative Breast Neoplasms · United States, Belgium, Korea, Republic of and more2CompletedAstraZenecaFeb 17, 201864
NCT02519348Carcinoma, Hepatocellular · United States, China, Hong Kong and more2Active, not recruitingAstraZenecaNov 6, 2020433
NCT02516241Urothelial Cancer · United States, Australia, Austria and more3Active, not recruitingAstraZenecaJan 27, 20201,126
NCT02453282Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaOct 4, 20181,118
NCT02369874Recurrence · United States, Argentina, Australia and more3CompletedAstraZenecaSep 10, 2018736
NCT02352948Non - Small Cell Lung Cancer NSCLC · United States, Australia, Belgium and more3CompletedAstraZenecaFeb 9, 2018597
NCT02340975Gastric or Gastroesophageal Junction Adenocarcinoma · United States, Canada, Japan and more2CompletedAstraZenecaApr 29, 2019114
NCT02319044Recurrence · United States, Australia, Belgium and more2CompletedAstraZenecaSep 26, 2016267
NCT02262741Squamous Cell Carcinoma of Head and Neck · United States, Canada1CompletedAstraZenecaSep 21, 201771
NCT02261220Advanced Solid Tumors · United States, Canada, France and more1CompletedAstraZenecaJan 27, 2020380
NCT02179671Carcinoma, Non-Small-Cell Lung · United States2CompletedAstraZenecaJun 11, 201632
NCT02141347Part A and B: Advanced Solid Malignancies · Japan1CompletedAstraZenecaJan 27, 201765
NCT02117219Myelodysplastic Syndromes · United States, France, Germany and more1CompletedAstraZenecaApr 30, 201967
NCT02000947Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more1CompletedAstraZenecaSep 17, 2019459
NCT01938612Squamous Cell Carcinoma of Head and Neck · Japan, Korea, Republic of, Taiwan1CompletedAstraZenecaMar 1, 2018269
NCT01843374Mesothelioma, Malignant · United States, Australia, Belgium and more2Active, not recruitingAstraZenecaJan 24, 2016571
NCT00585000Melanoma · United States1TerminatedAstraZenecaJan 201049
NCT00488995Acquired Immunodeficiency Syndrome2WithdrawnPfizer0
NCT00431275Melanoma · United States1CompletedAstraZenecaFeb 200885
NCT00378482Colorectal Neoplasms · United States, United Kingdom2CompletedAstraZenecaOct 27, 202337
NCT00372853Carcinoma, Renal Cell · United States1CompletedAstraZenecaMay 201028
NCT00313794Colorectal Neoplasms · United States, Canada2CompletedAstraZenecaJun 200849
NCT00312975Carcinoma, Non-Small-Cell Lung · United States, Canada, Czech Republic and more2CompletedAstraZenecaApr 200890
NCT00257205Melanoma · United States, Argentina, Australia and more3CompletedAstraZenecaAug 2010655
NCT00254579Melanoma · United States, Argentina, Australia and more2CompletedAstraZenecaDec 2009251
NCT00086489Melanoma · United States2CompletedAstraZenecaMay 2007118

How it is read

Names in the registry

  • “Tremelimumab”, 22 entries
  • “CP-675,206”, 12 entries
  • “tremelimumab”, 7 entries
  • “MEDI4736 + tremelimumab”, 3 entries
  • “MEDI4736 + Tremelimumab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.